MIFTEC and US Nuclear Join Race to Fill $7 Billion/Year Shortage of Medical Isotopes
Los Angeles, CA. June 5, 2018—US Nuclear Corp (OTCBB: UCLE) and MIFTEC recently signed a definitive agreement which formally appoints US Nuclear as the exclusive manufacturer of MIFTEC’s revolutionary medical isotope generators for North America and Asia, and makes US Nuclear a sales representative for all MIFTEC products. This definitive agreement replaces the Letter of Intent signed back in December 2017. MIFTEC’s parent company, MIFTI Nuclear Fusion, is a leader in developing fusion power and has shown that their staged Z-pinch fusion technique produces high neutron flux which can be used to produce medical isotopes at a fraction of the cost of current methods.
There are two main uses for medical isotopes: diagnosis and treatment. Diagnostic procedures using radioisotopes are now routine, and can be used to examine blood flow to the brain, functioning of the liver, lungs, heart, or kidneys—the advantage over other techniques being that you can image both bone and soft tissue, and assess what is happening physiologically. The most prominent treatment application is for cancer, using radiation to weaken or destroy targeted cancer cells.
There are no effective suppliers of medical isotopes in the USA and existing international suppliers cannot expand because of prohibitive costs and pollution problems. All new/existing competitors in the market rely on fission/cyclotrons/accelerators to produce the isotopes, which all require enriched uranium as a fuel supply, cost hundreds of millions of dollars to build, and could take up to 10 years or more to commission. This has resulted in a desperate shortage of radioisotopes and a huge unfilled demand.
MIFTEC’s fusion approach for generating medical isotopes uses heavy seawater for an unlimited fuel supply and poses no serious radiation issues. The design is extremely small compared to other methods, and could easily be placed at hospitals and medical facilities around the world. With rapid production at 50% of the current cost, many more patients will have the opportunity to receive these critical diagnostic scans and treatment, thereby saving hundreds of thousands of additional lives.
Robert Goldstein, CEO of US Nuclear Corp, commented, “Radioisotope sales were $9.6 billion in 2016 and projected to reach $17 billion by 2021, but with MIFTEC’s excellent efficiency and affordability, and US Nuclear’s manufacturing capability, we believe the world market will multiply.”
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at http://www.usnuclearcorp.com
CONTACT:
US Nuclear Corp. (OTCBB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com